Diagnosis, safety risks and tapering needs matter more
The FDA states that compounded drugs are "not reviewed by FDA prior to marketing and are not FDA-approved." What this means for consumers: When accessing compounded semaglutide or tirzepatide through telehealth platforms, you are receiving a medication that contains the same active ingredient as FDA-approved products but is prepared differently and has not undergone FDA approval as a finished product
Does tirzepatide burn fat or just suppress appetite
How many dosages are in a bottle
That means a clinician should review whether a patient has a history of relevant endocrine issues, pancreatitis, gallbladder problems, kidney concerns, chronic GI symptoms, or other conditions that may affect safety or treatment choice
She focuses on preventive health, including weight management to support better cardiovascular outcomes